单用表阿霉素缓释剂及联合表阿霉素游离剂腹腔化疗治疗肝癌的疗效

目的 观察单用表阿霉素(EPI)聚乳酸(PLA)缓释微球(MS)及联合游离表阿霉素(FEPI)腹腔化疗治疗肝癌的疗效.方法 将35只H_(22)腹水型肝癌荷瘤小鼠分为7组,每组5只,分别予空白微球,生理盐水,低、中、高剂量载药微球(分别含EP19、18、36mg/ks),FEPI(9mg/kg)和EPI-PLA-MS+FEPI(各含EPI4.5mg/kg),经腹腔注射给药,计算动物生命延长率.结果 EPI-PLA-MS能有效延长荷瘤鼠的生存时间,并呈量效关系,小鼠最大耐受量约为18～36 mg/kg.联合用药组的平均生存时间、中位生存时间和生命延长率均达到最高值,分别为(40.0 ± 16.9)d、33.5d和222.58%.结论 EPI-PLA-MS缓释剂与游离剂型联合腹腔化疗是一种新型、高效的给药方式,可有效治疗肝癌.

Efficacy of Intraperitoneally Injected Epirubicin-loaded Poly (D, L)-lactic Acid Microspheres Alone or Combined with Free Epirubicin in Treating Hepatocellular Carcinoma in Mice

Objective To explore the efficacy of intraperitoneally injected epirubicin (EPI) -loaded poly (d, l)-lactic acid (PLA) microspheres (MS) alone or combined with free epirubicin (FEPI) in treating hepatocellular carcinoma (HCC) in mice. Methods Mice that were transplanted with H_(22) ascites HCC were randomized into seven groups, which were intraperitoneally injected with blank microspheres, normal saline, three different doses of microspheres (9, 18, and 36 mg/kg EPI), FEPI (9 mg/kg), and the combination (microspheres with EPI 4. 5 mg/kg + FEPI 4. 5 mg/kg). The survival time of all animals was recorded.The rates of increase in life span of all the treatment groups were calculated. Results EPI-PLA-MS significantly prolonged the survival time of HCC mice in a dose-dependent manner, with a maximal tolerated dose (MTD) of 18 - 36 mg/kg. The combination group had the highest average survival time, median survival time, and rate of increase in life span, which were (40. 0 ± 16. 9) days, 33. 5 days, and 222. 58%, respectively. Conclusion EPI-PLA-MS combined with FEPI is highly effective in treating HCC in mice when intraperitoneally injected.